Maria Werner-Wasik, MD, on Lung Cancer Highlights: Expert Perspective

2017 ASTRO Annual Meeting

Maria Werner-Wasik, MD, of Thomas Jefferson University Hospital, summarizes a session on NSCLC that included discussion of a quality-of-life trial on optimizing treatment; chemotherapy and radiotherapy in advanced disease; a comparison of standard- vs high-dose conformal chemoradiotherapy; and long-term results on a comparison of two stereotactic body radiation therapy schedules in inoperable stage I disease (Abstracts 223, 224, 227, 33).

Gerard Morton, MD, on GU Highlights: Expert Perspective

Gerard Morton, MD, of Sunnybrook Odette Cancer Centre, summarizes a session that included discussion of late toxicities of radiotherapy for locally recurrent prostate cancer; using chemotherapy instead of radiation in early-stage seminoma; radiotherapy vs surgery plus radiotherapy in Gleason score 9–10 prostate cancer; and an analysis of the IROCK study on kidney cancer (Abstracts 1, 1089, 282, 330).

Lung Cancer

Jeffrey D. Bradley, MD, on NSCLC: Results of the RTOG 0617 Trial

Jeffrey D. Bradley, MD, of Washington University School of Medicine, discusses long-term phase III findings on standard-dose vs high-dose conformal chemoradiation therapy with or without cetuximab for stage III non–small cell lung cancer (Abstract 227).

Prostate Cancer

Juanita Crook, MD, on Prostate Cancer: Results From an NRG/RTOG Brachytherapy Trial

Juanita Crook, MD, of the University of British Columbia, discusses late toxicity findings on transperineal ultrasound–guided brachytherapy for locally recurrent prostate cancer after external-beam radiation therapy (Abstract 1).

Head and Neck Cancer

Bhishamjit S. Chera, MD, on Oropharyngeal Squamous Cell Carcinoma and HPV-16: Expert Perspective

Bhishamjit S. Chera, MD, of the University of North Carolina, discusses quantification of human papillomavirus 16 in circulating tumor DNA during de-intensified chemoradiation therapy for favorable-risk HPV-associated oropharyngeal squamous cell carcinoma (Presentation 92).

Prostate Cancer

Tamim Niazi, MDCM, on Prostate Cancer: Results From a Trial on Dose Escalation

Tamim Niazi, MDCM, of McGill University, discusses phase III study findings on hypofractionated, dose-escalation radiation therapy for high-risk adenocarcinoma of the prostate (Abstract 281).

Apr

Today In Oncology

Maria Werner-Wasik, MD, on Lung Cancer Highlights: Expert Perspective

Related Videos

Gerard Morton, MD, on GU Highlights: Expert Perspective

Jeffrey D. Bradley, MD, on NSCLC: Results of the RTOG 0617 Trial

Juanita Crook, MD, on Prostate Cancer: Results From an NRG/RTOG Brachytherapy Trial

Bhishamjit S. Chera, MD, on Oropharyngeal Squamous Cell Carcinoma and HPV-16: Expert Perspective

Tamim Niazi, MDCM, on Prostate Cancer: Results From a Trial on Dose Escalation

Proton Therapy and Intensity-Modulated Radiation Therapy for Localized Prostate Cancer

Local Excision May Be Feasible in Patients With Low Rectal Adenocarcinoma

Is Surgery Necessary to Treat Invasive Breast Cancer?

Smoking Status of the U.S. Cancer Population

Awareness of Alcohol Related Cancer Risks May Be Growing